Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer

NCT00237900 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00237900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00237900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Single.Centre, Phase I/II Study of ZD1839 (Iressa) in Combination With 5-Fluorouracil, Leucovorin and Radiotherapy in Subjects With Resectable Gastric Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2003
Completion date
February 29, 2004
Enrollment
34
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subjects with resectable local or locally advanced, non-metastatic (t2-t4, n0-n3, m0; stages ii and iii) and histologically-confirmed intestinal gc